Tilvestamab Biosimilar – Anti-AXL mAb – Research Grade

Description of Tilvestamab Biosimilar - Anti-AXL mAb - Research Grade

Introduction

Tilvestamab Biosimilar is a research-grade antibody that specifically targets the AXL receptor tyrosine kinase. AXL is a member of the TAM family of receptor tyrosine kinases and is known to play a crucial role in various cellular processes, including cell survival, proliferation, and migration. The overexpression of AXL has been linked to the progression of several types of cancer, making it an attractive therapeutic target. Tilvestamab Biosimilar is a monoclonal antibody that mimics the activity of the anti-AXL mAb, making it a promising candidate for cancer treatment.

Structure of Tilvestamab Biosimilar

Tilvestamab Biosimilar is a fully humanized monoclonal antibody that is produced in a mammalian expression system. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The antibody has a Y-shaped structure, with two antigen-binding fragments (Fab) and one crystallizable fragment (Fc). The Fab regions are responsible for binding to the AXL receptor, while the Fc region is involved in effector functions such as antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Mechanism of Action

Tilvestamab Biosimilar binds to the extracellular domain of AXL and prevents its interaction with its ligand, Gas6. This blocks the activation of downstream signaling pathways, including the PI3K/AKT and MAPK/ERK pathways, which are known to promote cell survival and proliferation. Additionally, the binding of Tilvestamab Biosimilar to AXL triggers internalization and degradation of the receptor, further reducing its activity. This dual mechanism of action makes Tilvestamab Biosimilar a potent inhibitor of AXL signaling.

Applications of Tilvestamab Biosimilar

Tilvestamab Biosimilar has shown promising results in preclinical studies as a potential therapeutic agent for various types of cancer. It has been shown to inhibit tumor growth and metastasis in several in vitro and in vivo models of cancer, including breast, lung, and pancreatic cancer. Additionally, Tilvestamab Biosimilar has been found to enhance the efficacy of other cancer treatments, such as chemotherapy and targeted therapy, when used in combination.

Advantages of Tilvestamab Biosimilar

Tilvestamab Biosimilar has several advantages over other AXL-targeting therapies. Being a fully humanized antibody, it is less likely to elicit an immune response in patients, making it a safer option for treatment. It also has a longer half-life in the body, allowing for less frequent dosing. Moreover, as a biosimilar, it is expected to have a lower cost compared to the original anti-AXL mAb, making it more accessible to patients.

Conclusion

Tilvestamab Biosimilar is a promising therapeutic candidate for the treatment of various types of cancer. Its specific targeting of the AXL receptor and its dual mechanism of action make it a potent inhibitor of AXL signaling. With its potential to enhance the efficacy of other cancer treatments and its advantages over other AXL-targeting therapies, Tilvestamab Biosimilar holds great promise for improving cancer treatment outcomes. Further clinical studies are needed to validate its efficacy and safety in human patients.

Keywords:

antibody, therapeutic target, AXL, receptor tyrosine kinase, monoclonal antibody, cancer treatment, biosimilar, Gas6, PI3K/AKT, MAPK/ERK, tumor growth, metastasis, chemotherapy, targeted therapy, immune response, biosimilar, cost.

SDS-PAGE for Tilvestamab Biosimilar - Anti-AXL mAb

Tilvestamab Biosimilar - Anti-AXL mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.